Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Holmberg C-J, Isaksson K, Ingvar C, et al. Prognostic significance of sentinel lymph node status in thick primary melanomas (>4mm). Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-14050-w.
2. Long GV, Luke JJ, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022;23(11):1378–88.
3. Varey AHR, Thompson JF, Howle JR, Lo SN, Ch’ng S, Carlino MS. Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary? Eur J Cancer. 2023;186:166–71.
4. Crystal JS, Thompson JF, et al. Therapeutic value of sentinel lymph node biopsy in patients with melanoma: a randomized clinical trial. JAMA Surg. 2022;157(9):835–42 (PMC9475390).
5. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8 (PMC6440712).